A1M Pharma initiates collaboration with Swedish CRO partner for clinical studies
Lund October 24, 2017. A1M Pharma has signed an agreement with the Swedish contract research organization Clinical Trials Consultants (CTC) about a collaboration for conducting the company's upcoming phase I/II studies. An initial safety study in healthy volunteers is scheduled to start in the first quarter of 2018.
– We are very pleased to initiate a collaboration with Swedish Clinical Trials Consultants for our planned clinical phase I/II studies. The company meets our strict requirements of experience and level of competence, and we expect an efficient collaboration as we are now able to conduct the studies in Sweden, says A1M Pharma's Head of Development Eddie Thordarson.
According to plan, A1M Pharma is currently in the process of designing the first three clinical sub-studies within the frame of the upcoming adaptive phase I/II study. The company is initially focusing on kidney protection in connection with PRRT radiation therapy, but the phase I/II study is also designed to form the basis for A1M Pharma's clinical development of a treatment for preeclampsia.
– I am pleased that A1M Pharma has chosen CTC Clinical Trials Consultants as CRO partner. A1M Pharma's upcoming clinical program is based on decades of innovative Swedish research, and we are really looking forward to collaborating with their research team, says CTC Clinical Trials Consultants CEO Anders Millerhovf.
About CTC Clinical Trials Consultants
CTC is a Swedish full-service CRO with focus on conducting clinical trials. Their mission is to facilitate clinical and translational research by providing customers with cost effective consultation as well as conducting early phase clinical trials (phase 0 / I / IIa). CTC has two dedicated clinical research units in Uppsala as well as two patient clinics in Uppsala and Linköping. For more information, please visit ctc-ab.se
For more information, please contact
Tomas Eriksson, CEO
Telephone: +46 46-286 50 30
About A1M Pharma
Several preclinical studies indicate that A1M Pharma’s candidate drug, ROSgard™, based on the endogenous protein Alpha-1-Microglobulin, restores impairments to kidney function by repairing damaged tissue and protecting against oxidative stress. Kidney injury is a condition which often occurs in connection with preeclampsia and which often limits the possibilities of using radiation therapies as a treatment for cancer. The company’s two indications are kidney protection in connection with Peptide Receptor Radionuclide Therapy (PRRT) – a targeted radiation therapy for cancer – with the aim of opening the possibility of increasing treatment levels and so fight metastatic cancer more effectively as well as treatment of preeclampsia. Every year, over 12 million people are affected by acute kidney injuries that can lead to permanent kidney damage. Preeclampsia affects around 10 million pregnant women worldwide and is responsible for 76,000 maternal and 500,000 infant deaths each year. A1M Pharma is listed on Nasdaq First North Stockholm since 20 June 2017. A1M Pharma’s Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
This information is information that A1M Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was provided, through the above contact, for publication on the 24 October 2017, at 14.30.